CellaVision AB (publ) CEVI.ST
Nasdaq Stockholm · Healthcare · Medical Devices
199.00 SEK
+0.5%
2026-11-06
Keep this stock on your watchlist and set email alerts for prices, reports and important announcements where available.
Annual accounts for CellaVision
| SEK million | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 639 | 677 | 723 | 759 |
| EBITDA | 191 | 207 | 220 | 235 |
| Net income | 118 | 130 | 141 | 153 |
| Balance sheet | ||||
| Equity | 642 | 716 | 816 | 888 |
| Total debt | 102 | 65 | 27 | 26 |
| Cash | 108 | 122 | 149 | 188 |
| Net debt | −6 | −57 | −123 | −163 |
| Ratios and per share | ||||
| EBITDA margin | 29.9% | 30.6% | 30.4% | 31.0% |
| Profit margin | 18.5% | 19.2% | 19.5% | 20.2% |
| Return on equity | 18.4% | 18.2% | 17.3% | 17.2% |
| Earnings/share (SEK) | 4.96 | 5.46 | 5.90 | 6.42 |
| Book value/share (SEK) | 26.90 | 30.04 | 34.20 | 37.21 |
| Shares outstanding (M) | 24 | 24 | 24 | 24 |
From the annual statements (Yahoo Finance), in the currency the company reports in. Per-share figures use the shares at the year end. Charts and annual figures →
Key figures
| P/E | 31.0 |
| P/B | 5.3 |
| EV / EBITDA | 19.5 |
| Net debt / EBITDA | −0.7 |
| Return on equity | 17.2% |
| Profit margin | 20.2% |
| Beta 1Y | 0.75 |
| Revenue growth 1Y | +4.9% |
| Revenue CAGR 3Y | +5.9% |
| Earnings/share CAGR 3Y | +9.0% |
| ROE avg. 3Y | 17.6% |
Ratios use the latest annual report that was public 90 days after the year end.
Dividends per share (SEK)
| 2026 | 2.75 |
| 2025 | 2.50 |
| 2024 | 2.25 |
| 2023 | 2.25 |
| 2022 | 2.00 |
Not investment advice. Figures may contain errors from the data source.